Conference Correspondent

Conference Correspondent

After 5 years of follow-up, single-agent ibrutinib continues to show durable responses in patients with treatment-naive or relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia, including those with del17p, del11q, or unmutated IGVH.
Page 12 of 12
Results 111 - 111 of 111
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME